共查询到20条相似文献,搜索用时 0 毫秒
1.
Effects of cianidanol on the blood lipid peroxide status in patients with chronic hepatitis 总被引:1,自引:0,他引:1
A Pár M Mézes P Németh T Jávor 《International journal of clinical pharmacology research》1985,5(6):389-397
This study was designed to investigate the effect of the natural bioflavonoid compound cianidanol on the blood lipid peroxide status of patients with chronic hepatitis. Nine patients had chronic active liver disease--seven of them hepatitis B virus-positive--and five had chronic alcoholic hepatitis. Besides some biochemical liver function tests (serum bilirubin, aminotransferases and gamma-glutamyl transferase), the changes in the serum level of malondialdehyde (a thiobarbituric acid reactive substance) as one of the end-products of lipid peroxidation, as well as the quantity/or activity of enzymes controlling peroxidation (superoxide dismutase (SOD), glutathione peroxidase and catalase) were measured. In addition, the serum level of the natural antioxidant vitamin E was followed-up. Cianidanol treatment (at a dose of 3.0 g/day for one month and of 1.5 g/day for two months) resulted in a slight improvement in aminotransferases and a significant fall (normalization) of high serum malondialdehyde level. After a marked transient increase, serum SOD content decreased while glutathione peroxidase and catalase activities as well as the vitamin E blood level increased during the treatment. Results suggest that (cianidanol in vivo inhibits lipid peroxidation and influences antioxidant enzyme systems and vitamin E in the blood of patients with chronic hepatitis. 相似文献
2.
Plasma vitamin E (alpha-tocopherol) concentrations were estimated by high performance liquid chromatography (HPLC) in 50 consecutively admitted chronic alcoholics (M = 44;F = 6;mean age +/- S.D. = 42.94 +/- 10.97;age range = 28-70 years) on admission and in 25 of them it was repeated during abstinence (6th day) while undergoing conventional detoxification therapy with polyvitamins (except vitamin E) and hypno-sedative drugs. Thirty percent of the patients were found to be deficient on admission and while on routine hospital diet during therapy, 20% of the patients were still deficient. It is, therefore, suggested that chronic alcoholics should be treated routinely with vitamin E along with other polyvitamins during detoxification in alcoholic units. 相似文献
3.
4.
McCreadie RG Halliday J Macewan T Hinselwood D Campbell G Paterson JR 《Journal of psychopharmacology (Oxford, England)》1996,10(4):295-297
Fourteen non-schizophrenic subjects were identified in a group general practice as taking antipsychotic medication. They were matched with a control group on age, gender and smoking status. Blood samples were taken to measure plasma lipid peroxide, serum vitamin E and cholesterol and vitamin E:cholesterol ratios. The majority of subjects were taking thioridazine (mean daily dose 42 mg, range 20-100 mg). There were no statistically significant differences between subjects and controls in any of the laboratory measures. The results in this small study therefore do not support the hypothesis that a possible source of increased free radical activity in schizophrenic patients is antipsychotic medication. 相似文献
5.
血清瘦素与慢性乙型肝炎合并酒精性肝病肝纤维化的关系 总被引:1,自引:1,他引:1
目的 研究血清瘦素与慢性乙型肝炎合并酒精性肝病(CHB+ALD)肝纤维化的关系.方法 选择CHB+ALD患者17例、肝硬化(LC)15例、慢性乙型肝炎(CHB)19例,以12例男性健康受试者(NC)为对照组.采用ELISA法测定各组血清瘦素水平,同步检测血清肝纤维化指标透明质酸(HA)、层粘连蛋白(IN)、前胶原蛋白(PCⅢ)和Ⅳ型胶原(Ⅳ-C),对结果进行分析.结果 CHB+ALD组血清瘦素水平(6.79±24.12)μg/L高于对照组(4.27±7.18) μg/L(P<0.05),单纯CHB组差异无统计学意义,CHB+ALD组患者肝纤维化四项指标高于单纯CHB组及NC组;CHB+ALD组血清瘦素水平与血清肝纤维化四项指标呈正相关(P<0.05或P<0.01).结论 血清瘦素是CHB+ALD患者肝纤维化形成的促进因子之一. 相似文献
6.
E González-Reimers M M Brajin-Rodríguez F Rodríguez-Moreno F Santolaria-Fernández N Batista-López H Alvarez-Argüelles A Milena A Rodríguez-Hernández 《Drug and alcohol dependence》1990,25(1):91-95
Liver fibrogenesis involves the synthesis of collagen fibrils and proteoglycans by various types of liver cells, including Ito cells, transitional cells, myofibroblasts and hepatocytes. Synthesis of collagen fibrils follows a complex metabolic pathway with intermediate products such as type III procollagen (III-PC). Serum levels of III-PC may reflect the activity of the fibrogenetic process. We analysed the relationship between the serum levels of III-PC (N-terminal peptide) and diverse clinical, biochemical and histological parameters of 77 alcoholic patients (27 cirrhotics), comparing them with those of 15 age- and sex-matched controls. A highly significant difference was obtained between controls and patients (P less than 0.0001), but no differences were observed between cirrhotics and non-cirrhotics. Serum III-PC significantly correlated with clinical and biochemical data of liver function derangement (prothrombin activity, serum albumin, bilirubin, gynecomastia, ascites, encephalopathy, edema, splenomegaly); with the duration of ethanol addiction and with MCV. Sixty patients were followed up for a period ranging between 3 and 1056 days (mean = 356 days); 9 of them died. Patients with III-PC levels above 38 ng/ml had a significantly higher mortality (P = 0.006) than those with levels under 38 (log rank test). Thus, serum III-PC may be a useful tool in the clinical evaluation and prognostic assessment of patients with chronic alcoholic liver disease. 相似文献
7.
Van de Casteele M Zaman Z Zeegers M Servaes R Fevery J Nevens F 《Alimentary pharmacology & therapeutics》2002,16(5):985-992
BACKGROUND: Enhanced production of reactive oxygen species may play a pathogenic role in alcoholic liver injury. AIMS: To investigate whether various antioxidant parameters in blood are affected in different stages of alcoholic liver disease and how specific the changes are relative to non-alcoholic cirrhosis. METHODS: Patients with alcohol abuse without cirrhosis (n=14), with alcoholic cirrhosis [Child-Pugh scores A (n=9), B (n=5) and C (n=18)] and with non-alcoholic cirrhosis [Child-Pugh score C (n=6)] and healthy controls (n=13) were studied. Levels of reduced glutathione and glutathione peroxidase activity in blood, erythrocytic superoxide dismutase activity and carotenoids, alpha-tocopherol and malondialdehyde in plasma were measured. RESULTS: Levels of reduced glutathione were significantly decreased in Child-Pugh score C cirrhotics, alcoholic or not in origin, whereas oxidized glutathione and glutathione peroxidase activity were not affected. Superoxide dismutase activity and alpha-tocopherol levels were not significantly different in the various groups. Carotenoid levels were significantly lower in alcoholic cirrhotics (Child-Pugh score C) vs. controls. Malondialdehyde levels were elevated only in cirrhotics Child-Pugh score C, alcoholic or non-alcoholic. CONCLUSIONS: Levels of reduced glutathione and malondialdehyde reflect the degree of liver impairment, more than the relation with alcohol intake. Decreases in several antioxidant levels are not specific to alcoholic liver injury. 相似文献
8.
Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. 总被引:1,自引:0,他引:1 下载免费PDF全文
L A Bauer T O'Sullivan W G Reiss J R Horn K Opheim D E Strandness R L Carithers 《British journal of clinical pharmacology》1994,37(4):375-381
Duplex scanning was used to measure liver blood flow (hepatic artery and main branches of the portal and hepatic veins) in six healthy subjects, five cirrhotic patients, and six hepatitis patients. Antipyrine clearance and formation clearances to its metabolites were also measured. Compared with healthy control subjects, cirrhotic patients had a lower hepatic vein blood flow (-76%, P < 0.05). This was due primarily to a lower portal vein blood flow (-36%, NS). A statistically significant difference in liver blood flow between patients with hepatitis and normal subjects was not detected. Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were significantly different in cirrhotic patients compared with the healthy subjects (mean +/- s.d.-healthy controls: t1/2 = 13.7 +/- 3.0 h, CL = 30.0 +/- 8.6 ml h-1 kg-1, AUC = 549 +/- 139 mg l-1 h; cirrhotic patients: t1/2 = 32.4 +/- 1.7 h, CL = 12.3 +/- 2.1 ml h-1 kg-1, AUC = 1061 +/- 218 mg l-1 h; P < 0.008). Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were not significantly different in hepatitis patients compared with the healthy subjects (hepatitis patients: t1/2 = 14.3 +/- 3.7 h, CL = 29.3 +/- 8.5 ml h-1 kg-1, AUC = 498 +/- 142 mg l-1 h). The volume of distribution of antipyrine was similar in all three groups of subjects.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
9.
目的:探讨尿毒症血液透析病人血清脂联素 (adiponectin)水平的变化; 了解血液透析病人血脂水平的变化以及脂联素与血脂的相关性, 分析脂联素对血脂的影响. 方法:应用ELISA法测定30例体检健康者与76例慢性肾衰尿毒症血液透析病人血清脂联素的水平;全自动生化分析仪测定血脂,包括甘油三酯(TG)、总胆固醇(TCh)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、脂蛋白a[Lp(a)]. 结果:尿毒症组病人血脂联素、TG、Lp(a)水平明显高于健康对照组(P<0.05或P<0.01) .尿毒症组病人血HDL-C明显低于健康对照组(P<0.05) .尿毒症病人血清脂联素与TG呈负相关,相关系数-0.42 (P<0.01);与HDL-C呈正相关,r为 0.33(P<0.05) .脂联素与TCh、LDL-C、Lp(a)无显著性相关. 结论: 尿毒症血液透析病人体内存在脂质代谢紊乱,表现为TG、Lp(a)水平升高,HDL-C水平下降.脂联素可能通过干预脂质代谢对尿毒症血液透析病人具有保护作用. 相似文献
10.
Lill JS O'Sullivan T Bauer LA Horn JR Carithers R Strandness DE Lau H Chan K Thakker K 《Journal of clinical pharmacology》2000,40(3):250-257
The objective of this study was to assess the pharmacokinetics of diclofenac sodium and its five metabolites following administration of a 150 mg oral dose to healthy subjects and patients with either chronic active hepatitis of varying morphology or alcoholic cirrhosis. Six healthy subjects, 6 chronic active hepatitis patients, and 6 alcoholic cirrhosis patients were enrolled in this prospective, open-label, parallel study. Blood samples were drawn at 0, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24, 48, 72, 144, 312, and 480 hours, and urine samples were collected for 144 hours after administration of a single oral dose of diclofenac sodium. The mean area under the serum concentration-time curve extrapolated to infinity, oral clearance, half-life, maximal concentration, and time to peak concentration for diclofenac and its metabolites were determined and compared using analysis of variance. Cirrhotics had a mean +/- SD diclofenac AUC value (19,114 +/- 6806 ng.h/ml) significantly different (p < 0.02) from hepatitis patients (6071 +/- 1867 ng.h/ml) and healthy subjects (7008 +/- 2006 ng.h/ml), whereas healthy subjects and hepatitis patients had similar values. Comparable results were found for 4'-hydroxydiclofenac. The AUC values for 3'-hydroxydiclofenac and 3'-hydroxy-4'methoxydiclofeanc were significantly different when healthy subjects were compared to cirrhotics. However, hepatitis subjects were not significantly different from either group. The results indicate that hepatitis does not alter the pharmacokinetics of diclofenac. Alcoholic cirrhosis increased the mean diclofenac AUC approximately three times compared to normal subjects, indicating that one-third of the usual dose in cirrhotics would produce equivalent AUC values in normal subjects and subjects with alcoholic cirrhosis. However, since pharmacodynamic measurements were not made and no increase in untoward or side effects was noted in the alcoholic cirrhosis patients after a single dose, maintenance doses should be titrated to patients response. 相似文献
11.
目的:分析非酒精性脂肪肝患者的血脂、血糖及肝功酶学指标的变化情况及检测意义。方法选取2012年1月~2014年8月在本院体检中发现的300例非酒精脂肪肝且无病毒性肝炎患者设为观察组,并选取本院同期接受体检的300例健康者作为对照组,对两组的血脂、血糖及肝功酶学指标进行检测和比较。结果观察组患者的血糖、血脂水平高于对照组,差异有统计学意义(P<0.05);观察组患者的GGT、ALT、AST水平分别为(53.20±9.37)、(54.88±9.08)、(53.58±7.89)U/L,显著高于对照组的(29.25±8.56)、(23.87±6.08)、(22.87±5.12) U/L(P<0.05)。结论加强非酒精性脂肪肝患者的血糖、血脂和肝功酶学指标监测有助于疾病的早期发现和防治,具有重要的临床价值。 相似文献
12.
Ogasawara F Fusegawa H Haruki Y Shiraishi K Watanabe N Matsuzaki S 《The Tokai journal of experimental and clinical medicine》2005,30(1):41-48
OBJECTIVE: To elucidate the mechanisms of thrombocytopenia in alcoholic liver diseases, we investigated activation status of platelets in patients with alcoholic fatty liver (Al-FL), alcoholic liver cirrhosis (Al-LC) or hepatitis-C liver cirrhosis C (C-LC). METHODS: Platelet activation was evaluated by flow cytometry using monoclonal antibodies against P-selectin (CD62P) and the fibrinogen receptor (PAC-1), both specific for platelet activation, and anti-CD61 antibody for the presence of microparticles (PMP) in seven patients with Al-FL, thirteen patients with Al-LC and, as a non-alcoholic liver disease control, nine patients with C-LC. As a normal control, seventeen healthy subjects without liver dysfunction were also evaluated. RESULTS: Compared with the healthy controls, the platelet count was significantly decreased in patients with alcoholic liver diseases or C-LC. Ten days after discontinuation of alcohol intake, the platelet count was significantly higher in both the Al-FL and Al-LC groups than that measured on admission. There was an inverse correlation between the platelet count and PMP, a marker of platelet activation. The Al-FL, Al-LC and C-LC groups showed significantly higher percentages of platelets positive for CD62P than the healthy controls. The PAC-1 positivity was increased only in the C-LC group. PMP were significantly increased in the Al-FL, Al-LC and C-LC groups compared to that in the healthy group. In the Al-LC group, PMP were significantly decreased 10 days after discontinuation of alcohol intake from that measured on admission. CONCLUSION: Patients with alcoholic liver diseases have increased platelet activation, which may contribute to the occurrence of thrombocytopenia. The formation of PMP might be one of the important factors of thrombocytopenia in alcoholic liver diseases. 相似文献
13.
Evidence regarding the outcomes of viral super-infection in patients with chronic liver disease and practical strategies for hepatitis A and B vaccination of these individuals are reviewed. Patients with acute hepatitis A and chronic hepatitis B have a more severe clinical course and a higher death rate compared with otherwise healthy individuals with hepatitis A, and these differences are most pronounced in older patients and those with histological evidence of chronic hepatitis or cirrhosis, rather than in asymptomatic hepatitis B carriers. Patients with acute hepatitis A super-infection and chronic hepatitis C have an increased risk of fulminant hepatitis and death. In addition, patients with other chronic liver diseases also appear to be at increased risk for more severe disease with superimposed hepatitis A. Patients with chronic hepatitis B and hepatitis C virus co-infection have more severe laboratory abnormalities, more severe histological disease, a greater frequency of cirrhosis and complications of cirrhosis, and a higher incidence of hepatocellular carcinoma. Vaccines for both hepatitis A and B are safe and effective if used early in the course of chronic liver disease. Hepatitis A and B vaccination should be part of the routine management of patients with chronic liver disease, preferably as early as possible in the natural course of their disease. 相似文献
14.
目的:探讨不同基因型(GT)慢性乙型肝炎(乙肝)患者体内黄嘌呤氧化酶和维生素E水平,阐明患者体内氧化损伤的情况。方法:检测30例慢性乙肝患者的基因型、氧化损伤指标(黄嘌呤氧化酶和维生素E)、肝功能、乙型肝炎病毒(HBV)DNA,并做出统计分析。结果:慢性乙肝患者基因型C型组与B型组比较:血清中ALT水平高,黄嘌呤氧化酶水平明显升高,维生素E水平明显降低。在基因型B型、C型及全部乙肝患者体内,黄嘌呤氧化酶浓度与ALT水平呈明显正相关,维生素E浓度与ALT水平呈明显负相关;黄嘌呤氧化酶浓度与维生素E浓度与HBVDNA水平无明显相关。结论:基因型C型患者较基因型B型患者体内存在较严重的氧化损伤。氧化损伤是引起基因型C型患者出现较重临床表现的重要机制。HBVDNA的水平与患者的基因型及氧化损伤水平无明显关系。 相似文献
15.
Erythrocytes from alcoholics without liver cirrhosis and control subjects were examined for the susceptibility to lipid peroxidation. Erythrocytes of patients were found to be sensitive to H2O2-induced peroxidation as compared to controls. In addition, chronic alcoholics showed a high level of plasma lipid peroxide levels. These results suggest the stimulation of lipid peroxidation in chronic alcoholics. 相似文献
16.
17.
Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease 总被引:2,自引:0,他引:2
Nobili V Manco M Devito R Ciampalini P Piemonte F Marcellini M 《Alimentary pharmacology & therapeutics》2006,24(11-12):1553-1561
BACKGROUND: Few data are available on the effect of antioxidants in paediatric non-alcoholic fatty liver disease (NAFLD). AIM: To compare the effect of a nutritional programme alone or combined with alpha-tocopherol and ascorbic acid on alanine aminotransferase (ALT) levels, and insulin resistance (IR) in biopsy-proven NAFLD children. METHODS: IN a 12-month double-blind placebo study, 90 patients were prescribed a balanced calorie diet (25-30 cal/kg/d), physical exercise, and placebo (group A) or alpha-tocopherol 600 IU/day plus ascorbic acid 500 mg/day (group B). IR was estimated by the homeostasis model assessment (HOMA-IR). RESULTS: At month 12, ALT (32.67 +/- 8.09 vs. 32.18 +/- 11.39 IU/L; P = NS), HOMA-IR (1.52 +/- 0.66 vs. 1.84 +/- 0.95 IU/L; P = NS), and weight loss (32% vs. 35% of excessive body weight; P = NS) did not differ between the two arms. Among subjects who lost >or=20% of their excessive weight, ALT and body weight percentage changes were significantly related (r(o) = 0.260; P = 0.03). In subjects, who lost more than 1.0 kg, HOMA-IR significantly decreased (2.20 +/- 0.21 to 1.57 +/- 0.13 in group A (P 相似文献
18.
The tocotrienol vitamin E has potent antioxidant property, however absorption is low due to high lipid solubility. A self emulsifying preparation of tocotrienol rich vitamin E (SF-TRE) had been reported to increase their bioavailability. This randomized, placebo controlled, blinded end point clinical study aimed to determine the effects of 50, 100 and 200 mg daily of SF-TRE and placebo for two months on arterial compliance and vitamin E blood levels. Assessment of arterial compliance by carotid femoral pulse wave velocity (PWV) and augmentation index (AI), plasma vitamin E, serum total cholesterol and low density lipoprotein cholesterol were taken before and after 2 months' treatment in 36 healthy males. Un-supplemented tocotrienol levels were low, after treatment, all SF-TRE treated groups had significantly higher plasma alpha, delta and delta tocotrienol concentrations compared to placebo. Augmentation index change from baseline to end of treatment for groups placebo, 50, 100, and 200 mg were 2.22+/-1.54, -6.59+/-2.84, -8.72+/-3.77, and -6.27+/-2.67% respectively (p=0.049, 0.049, and 0.047 respectively). Groups 100 and 200 mg showed significant improvement after treatment with pulse wave velocity reductions of 0.77 m/s and 0.65 m/s respectively (p=0.007 and p=0.002). There was no effect of SF-TRE on serum lipids. We conclude that there was a trend towards improvement in arterial compliance with 2 months' of SF-TRE. 相似文献
19.
目的 探讨活性维生素D用于慢性肾脏疾病的治疗效果。方法 检索Ovide Medline、CINAHL、Embase、CochraneCentral Register of Controlled Trials、中国学术期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、万方数据库(Wangfang)和维普中文科技期刊数据库(VIP)等数据库,收集活性维生素D用于慢性肾脏疾病治疗的临床随机对照研究(RCT),检索年限均为2005年1月—2018年6月。采用Revman 5.3软件进行数据分析。结果 共纳入18个RCTs,Jadad量表评分均≥2分。治疗后试验组超敏C-反应蛋白(hs-CRP)[MD=-1.10,95% CI(-1.72,-0.49),P<0.05]、白介素6(IL-6)[MD=-23.77, 95% CI(-38.32,-9.22), P<0.05]与肿瘤坏死因子-α(TNF-α)[MD=-120.28,95% CI(-177.02,-63.54),P<0.05]降低幅度均高于对照组,两组比较差异显著(P<0.05);试验组血肌酐(SCr)、24h尿蛋白定量与血尿素氮(BUN)降低幅度均高于对照组(P<0.05)。试验组血清甲状旁腺激素水平[MD=-10.87,95% CI(-13.44,8.30),P<0.05]降低幅度高于对照组。结论 活性维生素D可降低CKD患者微炎症,改善患者肾功能,预防继发性甲状旁腺功能亢进。 相似文献
20.
张凌 《临床药物治疗杂志》2012,10(2):18-22
慢性肾脏病(CKD)患者的预期寿命比较短,绝大多数是因为该人群心血管事件的发生率和死亡率比较高。CKD的进展、矿物质紊乱和骨病、维生素D代谢障碍、继发性甲状旁腺功能亢进和血管钙化等疾病,都与CKD患者死亡率高的发病机制相关。活性维生素D在CKD患者中能预防和治疗骨病作用的同时,也具有预防心血管异常及降低蛋白尿和纤维化的潜在作用。CKD患者使用维生素D和维生素D受体激动药(VDRA)主要以血清甲状旁腺激素(PTH)浓度为指导。维生素D治疗CKD患者的25(OH)Vit D缺乏。如果存在甲状旁腺功能亢进,应该使用VDRA治疗,选择性VDRA可以避免高钙磷血症,钙敏感受体激动剂配合VDRA的疗效更佳。 相似文献